WILLIAM PEACOCK to Anticoagulants
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Anticoagulants.
Connection Strength
2.720
-
Safety of direct oral anticoagulants: insights from postmarketing studies. Am J Emerg Med. 2016 Nov; 34(11S):9-13.
Score: 0.380
-
Target-specific Oral Anticoagulants in the Emergency Department. J Emerg Med. 2016 Feb; 50(2):246-57.
Score: 0.358
-
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers. Hosp Pract (1995). 2014 Oct; 42(4):75-82.
Score: 0.331
-
Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012 Dec; 35(12):730-7.
Score: 0.284
-
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28:10760296221120421.
Score: 0.137
-
Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2020 10; 76(4):470-485.
Score: 0.118
-
Reducing the hospital burden associated with the treatment of pulmonary embolism. J Thromb Haemost. 2019 05; 17(5):720-736.
Score: 0.113
-
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. Curr Med Res Opin. 2017 09; 33(9):1717-1723.
Score: 0.101
-
Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin. 2017 09; 33(9):1697-1703.
Score: 0.100
-
Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism. Clin Ther. 2017 Jul; 39(7):1426-1436.e2.
Score: 0.100
-
Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Heart Lung Circ. 2018 Mar; 27(3):390-393.
Score: 0.099
-
Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
Score: 0.097
-
Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Acad Emerg Med. 2016 11; 23(11):1280-1286.
Score: 0.096
-
Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis. Curr Med Res Opin. 2016 06; 32(6):1117-20.
Score: 0.092
-
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. Crit Pathw Cardiol. 2013 Sep; 12(3):107-15.
Score: 0.077
-
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 01; 104(9):1171-8.
Score: 0.059
-
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. J Invasive Cardiol. 2004 Feb; 16(2):46-51.
Score: 0.040
-
Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. Clin Cardiol. 2009 Dec; 32(12):668-75.
Score: 0.030
-
Benefit of early discharge among patients with low-risk pulmonary embolism. PLoS One. 2017; 12(10):e0185022.
Score: 0.026
-
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017 08; 48(8):2142-2149.
Score: 0.025
-
Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.
Score: 0.024
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.024
-
Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2006 Jun 15; 97(12):1707-12.
Score: 0.012